Examiner Cite

No

Initial\*

Patent Number

Remove

Figures Appear

Pages,Columns,Lines where

Relevant Passages or Relevant

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10591243		
	Filing Date		2006-08-31		
	First Named Inventor Fernandez de Castro		ndez de Castro		
	Art Unit		1616		
	Examiner Name	Chui, Mei Ping			
	Attornov Docket Numb	~	23005US04		

Kind

Code<sup>1</sup> Issue Date

U.S. PATENTS

Name of Patentee or Applicant

of cited Document

	1	7	597898		2009-10	0-06	Birkel et al.				
	2	7.	850048		2010-12	2-14	Arminak				
	3	4	225456		1980-0	3-30	Schmidt et al.				
If you wis	h to ac	id a	dditional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
				U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*		Cite No Publication Number			Publication Name of Patentee or Applica of cited Document			Rele	es,Columns,Lines where want Passages or Relev es Appear		
	1		20080178899	A1	2008-07	7-31	Moenks et al.				
If you wis	h to ac	ld a	dditional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Ad	d butto	on. Add	
					FORE	GN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No		reign Document mber <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Ts
				_							_

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10591243	
iling Date		2006-08-31	
irst Named Inventor	Fema	ndez de Castro	
Art Unit		1616	
Examiner Name	Chui,	Chui, Mei Ping	
Attorney Docket Number		23995US01	

Date Considered

		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, burntl, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city	Тs
	1	Notice of Reasons for Rejection for Canadian Patent Application No. 2008-500017 mailed January 17, 2012	
	2	Mason Chemical Company, brochure for Masurf FS-115/FS-130 100504	
	3	Decision in the Opposition to European Patent No. 1 811 013 B1 (including Auxiliary Requests) dated April 10, 2012	
	4	Notice of Reasons for Rejection for Canadian Patent Application No. 2008-500017 mailed May 31, 2011	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a 1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER SIGNATURE

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10591243	
Filing Date		2006-08-31	
First Named Inventor	Fernandez de Castro		
Art Unit		1616	
Examiner Name	Chui, Mei Ping		
Attorney Docket Number		23995US01	

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.5(r)(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael B. Harlin/	Date (YYYY-MM-DD)	2012-04-18
Name/Print	Michael B. Harlin	Registration Number	43658

This collection of information is required by 3T CRR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR.

1.14. This collection is estimated to take if hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. operatment of Comments of Control (SA), Assandria, VAS 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VAS 2213-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
  the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
  may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
  an application which became abandoned or in which the proceedings were terminated and which application is
  referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.